James P. Allison

James P. Allison is a Director and High Senior Professor at The University of Texas MD Anderson Cancer Center. A pioneer in immunology and oncology, his research centers on immune checkpoint inhibitors, including anti-CTLA-4 and anti-PD-1 therapies, and the cellular mechanisms governing immune responses in cancer. His latest work, published in Nature and PNAS (2025), reveals how cancer-induced nerve injury promotes resistance to anti-PD-1 therapy and how anti-CTLA-4 generates superior memory responses via TCF-1. He also investigates the IL-6/IL-23/Th17 axis in immunotherapy toxicity and neurotransmitter modulation, such as dopamine beta-hydroxylase targeting, to enhance checkpoint blockade efficacy in melanoma. His research further explores tumour cell mimicry of erythroblasts to hijack iron and local Treg cell loss in reprogramming systemic antitumour immunity. Internationally recognized for his foundational contributions to cancer immunotherapy, his work continues to shape therapeutic strategies and translational oncology.